SEMINARS IN OPHTHALMOLOGY, cilt.36, sa.8, ss.794-799, 2021 (SCI-Expanded)
Aim: Nivolumab is an immune checkpoint inhibitor that has recently been widely used for metastatic malignant melanoma. We report a case who developed multiple different ocular immune-related side effects (iRAEs) related to nivolumab.